Verification of the Utility of Urinary L-FABP as a Predictor of Impaired Renal Function Based on Its Relationship with Changes in Renal Function
<b>Background:</b> In patients with diabetes or hypertension, if appropriate intervention is not initiated early in the course of kidney disease, not only does the risk of progressing to end-stage renal failure increase, but mortality associated with vascular complications also rises as the disease progresses; therefore, there is an urgent need to develop urinary biomarkers that enable early diagnosis and prediction of disease progression. <b>Methods:</b> This two-year prospective observational study involved 185 outpatients. Patients were classified into two groups based on their baseline urinary L-FABP levels relative to the reference value of 8.4 μg/g·Cr at the start of the study. The rate of eGFR decline during the observation period was evaluated. <b>Results:</b> The results showed an interaction (synergistic effect) between urinary L-FABP and time in patients with diabetes or hypertension who had an eGFR of at least 60 mL/min/1.732 m<sup>2</sup>/kg/1.732 m<sup>2</sup>. Patients with high urinary L-FABP levels (>8.4 μg/g·Cr) exhibited a notably faster eGFR decline compared with those with low levels (≤8.4 μg/g·Cr). This finding suggests the potential of urinary L-FABP as a predictor of renal function decline; we evaluated this utility using the area under the ROC curve (AUC) and logistic regression analysis. The results indicate that urinary L-FABP holds potential as a predictor of renal function decline in diabetic or hypertensive patients with preserved eGFR. <b>Conclusions:</b> Among the analysis groups in which the validation was conducted, it was demonstrated that urinary L-FABP holds potential as a predictor of renal function decline in patients with diabetes or hypertension who have a maintained eGFR. Given that urinary L-FABP is thought to reflect tubulointerstitial damage associated with renal microcirculatory impairment, its future utility as a urinary biomarker for the early diagnosis and prognosis of chronic kidney disease (CKD) is anticipated.
Authors
- Takeshi Sugaya (ORCID: https://orcid.org/0000-0002-4387-8046)
- Yusuke Kato (ORCID: https://orcid.org/0000-0003-2424-4571)
Institutions
- St. Marianna University School of Medicine (JP)
- Kumamoto Medical Center (JP)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-03-16
- DOI
- https://doi.org/10.3390/jcm15062243
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.00